Meptazinol is an opioid drug having mixed agonist-antagonist properties. Chemically it is a hexahydroazepine derivative. It has been used to provide postoperative analgesia i ,2 for patients undergoing abdominal surgery but only in single dose studies. The drug is of particular interest in that the clinical impression of minimal ventilatory depression has been confirmed,3 60 mg meptazinol showing less ventilatory depression than 10 mg of morphine. To test its efficacy in patients undergoing abdominal surgery and to assess the incidence of side effects, an open study was undertaken in 43 patients.
At time zero (when the first dose of meptazinol was given) and then after half, one, one and a half, two, three, four, five and six hours, the observer recorded pain intensity as none, slight, moderate or severe. At the same time, degree of sedation was recorded as asleep, very drowsy, drowsy or awake. Blood pressure, pulse rate and respiratory rate were also recorded as were the occurrence of nausea and vomiting or any other observed and volunteered side effects. The patients were followed up in the wards during the time for which analgesics were required. Further enquiry was made regarding times of drug administration and to establish any side effects potentially related to the drug.
RESULTS
Forty-three patients completed the trial. Their mean age was 47 years with a range from 19-82 years. Fifteen were male. Their mean weight was 69 kg with a range from 40-107 kg ( Table 3 ). The range of surgical procedures is shown in Table 1 . Although the mean number of injections of meptazinol in the first 24 hours was six, the range of 1-10 injections for that period should be noted. For the entire period during which meptazinol was given, the mean number of injections per patient was seven but the range was 2-19. The variability of need for pain relief is also apparent from the duration of effect of each dose as shown in Table 2 . For the first dose of meptazinol, the mean duration of effect was 2.9 hours with subsequent doses lasting an average of 4.1-6.6 hours. However, the needs of individual patients were infinitely more variable. Data was only included in the table when a further dose of meptazinol was given so as to establish a finite end point for that dose. The use of meptazinol was also examined by calculating the dose during the first 24 hours from surgery and (to reduce the bias caused by variations in body fat) as mg/metre 2 of body area. (Body surface area was derived from standard tables.) This value is shown in Table 3 and again emphasises the wide range of drug requirement. An attempt was made to correlate the drug requirement expressed as mg/m 2 124 hours with patient age, using the calculation of a linear regression line by the method of least squares. A correlation coefficient of 0.32 was The pain experienced by the patients during the six-hour observation period has been expressed as a mean pain score, firstly in respect of all doses of medication given during this time (Figure 1) . Secondly, the pain score at each observation has been subtracted from that at the time of administration of meptazinol to produce a rating of the Pain Intensity Difference. When pain became severe again within the six-hour period so as to necessitate a further dose of meptazinol, the pain was assumed to continue at the original level. By this means, the effect of a single dose of the drug was established for this group of patients. This is shown in Figure 2 . A survey of the degree of sedation during the intensive observation period showed that the patients remained mildly to moderately sedated throughout the study.
Sixteen patients vomited prior to the administration of meptazinol and four of these did not vomit again. A further 20 patients were observed to have moderate to severe nausea or vomiting during the initial observation period. Fourteen patients reported further nausea with vomiting during the period 24-48 hours from surgery.
Antiemetic medication (metaclopramide or prochlorperazine) was given to 15 patients once and to 17 patients more than once. The data is presented in Table   5 . One patient complained of severe dizziness, one of feeling very drowsy. Marked sweating, not accompanied by any cardiovascular disturbance was observed in one patient. No hallucinatory experiences were reported.
DISCUSSION
Meptazinol given in a dose of 100 mg by intramuscular injection produced satisfactory pain relief in the majority of patients in whom it was used. It was interesting to note the shorter mean duration of action of the first doses given after operation, presumably representing the time required for the reaching of a therapeutic level of the drug as a result of its redistribution and metabolism in the body. The longer mean intervals between later doses emphasises the need to distinguish between single and multiple doses when considering its duration of effect. The wide range of times between doses of the drug in different patients is of important practical implication. Some patients receive 10 times as much drug as others in the same period (24 hours).
It is not clear from the data of Moyes and colleagues 2 whether there was a similar variability in the time until the next dose of analgesic. Paymaster l gives the mean time to administration of the second analgesic as 3.9 hours with a standard error of the mean as 0.3 hours. Expressing the data from the present trial in the same manner the equivalent dose lasted 2.9 hours with standard error of the mean of 0.6 hours suggesting a greater variability and the time at which a second analgesic was deemed necessary. It should be noted that all patients had undergone abdominal surgery as compared with 60070 in Paymaster's study so that the overall amount of pain may have been higher in the present study.
Of particular interest in the present study is the high incidence of nausea and vomiting. Comparison with other published series is difficult due to the different times for data collection. Nevertheless, the incidence appears high in comparison with that reported by Paymaster l or Moyes and colleagues 2 • A study! reported from this department showed a 32% incidence of moderate to severe nausea after pethidine. Even if only those patients vomiting after the first dose of meptazinol are included, the incidence from the present study is 47%. The patient groups in these two studies were similar in that anaesthetic techniques were the same and all patients had undergone abdominal surgery. The high incidence in the present study must be considered against the background of higher overall incidence from this department than is the case in most series.
Circulatory and respiratory changes following meptazinol were insignificant in the six-hour observation period in keeping with the observations of Jordan and colleagues 3 notwithstanding the higher dose level in the present study. Meptazinol produces satisfactory analgesia for abdominal surgery but the dose required to give a sufficient effect is extremely variable. This variability has been found in other studies carried out in this department. It points to the need for the importance of a flexible approach to analgesia and suggests that the traditional regimen of a four-hourly intramuscular injection of meptazinol 100 mg will produce adequate analgesia only in a minority of patients with severe pain.
Although the cardio-respiratory effects of the drug were minimal in this group of patients, the high incidence of significant nausea and vomiting was very distressing for some patients. It is unlikely we will be using meptazinol extensively for the treatment of postoperative pain.
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